Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
NCT04797780 is registered in ClinicalTrials.gov with Syros Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
- Lead sponsor
- Syros Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- February 8, 2021
- Completion date
- November 13, 2024
- Enrollment
- 246 (actual)
- Sites
- 128
Conditions
As the registry lists them; a condition with its own page is linked.